Swedish Orphan Biovitrum ABSWOBY 67 ROA % is 7.08% as of Mar. 2026, which is 14% above its 10-year median of 6.22. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.17 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 57.95% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Swedish Orphan Biovitrum AB's annualizedNet Income for the quarter that ended in Mar. 2026 was $566 Mil.
Swedish Orphan Biovitrum AB's average Total Assets over the quarter that ended in Mar. 2026 was $7,989 Mil. Therefore, Swedish Orphan Biovitrum AB's annualized ROA % for the quarter that ended in Mar. 2026 was 7.08%.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's ROA % or its related term are showing as below:
SWOBY'
s ROA % Range Over the Past 10 Years
Min: 0.67 Med: 6.22 Max: 17.22
Current: 1.3
During the past 13 years, Swedish Orphan Biovitrum AB's highest ROA % was 17.22%. The lowest was 0.67%. And the median was 6.22%.
SWOBY's ROA % is ranked worse than 57.95% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.685
vs SWOBY: 1.30
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's ROA % distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Swedish Orphan Biovitrum AB (SWOBY) has a ROA % of 7.08% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is 14% above median its historical median of 6.22. Over the past decade, Swedish Orphan Biovitrum AB's ROA % has ranged from 0.67 to 17.22. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #583 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 58%.
Is Swedish Orphan Biovitrum AB's ROA % too high?
Swedish Orphan Biovitrum AB's current ROA % of 7.08% is 14% above median its 10-year median of 6.22. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 17.22. The Drug Manufacturers industry median ROA % is 2.69. Swedish Orphan Biovitrum AB's value of 7.08% is 163.7% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #583 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #583 out of 1006 companies for ROA %. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median ROA % is 2.69. Swedish Orphan Biovitrum AB's value of 7.08% is 163.7% above this benchmark. Historically, Swedish Orphan Biovitrum AB's own ROA % has ranged from 0.67 to 17.22 over the past decade. While the company's 10-year median is 6.22 vs. the industry median of 2.69, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current ROA % of 7.08% is 163.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current ROA % is 7.08%, which is 14% above median its own 10-year median of 6.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.17, compared to a current price of $23.18 — trading 35% above its estimated fair value. The current ROA % is 7.08%, which is 14% above median its 10-year median of 6.22 and 163.7% above the Drug Manufacturers industry median of 2.69. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current ROA % is 7.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.18 is trading 35% above its estimated GF Value™ of $17.17.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
ROA %: 7.08% (14% above median its 10-year median of 6.22)
GF Value™: $17.17 vs. price of $23.18 (35% above fair value)
Industry Position: 163.7% above the Drug Manufacturers median (#583 of 1006)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
